BioChaperone Glargine + liraglutide

BioChaperone Glargine + liraglutide is an investigational combination therapy developed by Adocia for the treatment of diabetes. It combines insulin glargine, a long-acting basal insulin analogue, with liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, into a single formulation. The product utilizes Adocia's proprietary BioChaperone technology, which employs a physical complexation with a specialty excipient to enable the stable co-formulation of these two peptides at a neutral pH, which is typically challenging due to their differing solubility profiles. By combining these two agents, the therapy aims to provide comprehensive glycemic control by addressing both fasting and postprandial glucose levels while potentially mitigating weight gain associated with insulin therapy.

Other names

BioChaperone Glargine Liraglutide